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ABSTRACT In small studies and cases series, a history of tuberculosis has been associated with both
airflow obstruction, which is characteristic of chronic obstructive pulmonary disease, and restrictive
patterns on spirometry. The objective of the present study was to assess the association between a history
of tuberculosis and airflow obstruction and spirometric abnormalities in adults.
The study was performed in adults, aged 40 years and above, who took part in the multicentre, cross-
sectional, general population-based Burden of Obstructive Lung Disease study, and had provided
acceptable post-bronchodilator spirometry measurements and information on a history of tuberculosis.
The associations between a history of tuberculosis and airflow obstruction and spirometric restriction were
assessed within each participating centre, and estimates combined using meta-analysis. These estimates
were stratified by high- and low/middle-income countries, according to gross national income.
A self-reported history of tuberculosis was associated with airflow obstruction (adjusted odds ratio 2.51,
95% CI 1.83–3.42) and spirometric restriction (adjusted odds ratio 2.13, 95% CI 1.42–3.19).
A history of tuberculosis was associated with both airflow obstruction and spirometric restriction, and
should be considered as a potentially important cause of obstructive disease and low lung function,
particularly where tuberculosis is common.
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Introduction
In 2012, there were an estimated 8.6 million new cases of tuberculosis worldwide [1], with South-East
Asia, Western Pacific Regions and Africa accounting for more than 75% of the toll. More than 30% of the
world population may have latent tuberculosis but only 5–20% of them develop active tuberculosis at some
point in their lifetime [1, 2]. Those who survive it usually show post-treatment sequelae in the lung that
may contribute to reduced quality of life and disability [3–5].
Airflow obstruction is characteristic of chronic obstructive pulmonary disease (COPD) and its main risk
factor is tobacco smoking [6, 7]. However, more than 20% of patients satisfying the criteria for COPD do
not have a history of tobacco smoking [8, 9]. Among other potential risk factors, a history of tuberculosis
has been suggested by several studies as a strong predictor of chronic airflow obstruction that could
explain COPD among nonsmokers [9–11]. With some exceptions, most of these studies were small
(n<1000), not population-based (i.e. participants not randomly selected from general population) and
limited to a single centre or country, and several used pre-bronchodilator instead of post-bronchodilator
spirometric measurements [11].
Spirometric restriction is characteristic of restrictive lung diseases and has been reported as a consequence
of tuberculosis since the late 1910s [12, 13]. More recent epidemiological studies of South African miners
and hospital-based cases have suggested that a history of tuberculosis and increasing number of events of
this disease may lead to a deficit in lung function [14–18]. However, population data to support the
association between a history of tuberculosis and spirometric restriction are lacking.
The aim of the present analysis was to assess the association of airflow obstruction and spirometric
restriction with a history of tuberculosis in the large, international, population-based, Burden of Obstructive
Lung Disease (BOLD) study.
Methods
Participants
The design and rationale for the BOLD study have been reported elsewhere [19]. Noninstitutionalised
adults aged 40 years and older were sampled and invited to take part in the study. Sampling plans
designed to randomly recruit a representative sample of the population at all study sites were used.
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Of the 21962 participants who responded to the core questionnaire, 18669 had acceptable
post-bronchodilator spirometry, and of these, 18664 answered a question on history of tuberculosis. Data
were available from 27 sites, but Sydney (Australia), Mumbai and Srinagar (India), Penang (Malaysia), Ife
(Nigeria), Bergen (Norway), Sousse (Tunisia) and Adana (Turkey), which each contained less than five
participants with history of tuberculosis, were excluded; therefore, the present study population consists of
14050 participants from 19 sites.
The countries and sites represented in this analysis are: Tirana, Albania; Annaba, Algeria; Salzburg,
Austria; Vancouver, BC, Canada; Guangzhou, China; London, UK; Tartu, Estonia; Hannover, Germany;
Reykjavik, Iceland; Pune, India; Fes, Morocco; Maastricht, the Netherlands; Manila, Nampicuan and
Talugtug, the Philippines; Krakow, Poland; Lisbon, Portugal; Cape Town, South Africa; Uppsala, Sweden;
and Lexington, KY, USA. All sites received approval from their local ethics committee and participants
provided written informed consent.
History of tuberculosis
Face-to-face interviews were conducted by trained and certified staff in the native language of the
participant in order to collect information on respiratory symptoms, health status and exposure to risk
factors. A history of tuberculosis was defined as a positive answer to the question “Has a doctor or other
health care provider ever told you that you have tuberculosis?”. Participants who were on treatment for
tuberculosis at the time of the study were excluded from participation.
Outcome measures
Lung function, including forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC), was
measured using the ndd EasyOne Spirometer (ndd Medizintechnik AG, Zurich, Switzerland) before and
15 min after administration of salbutamol (200 μg) from a metered-dose inhaler through a spacer. The
BOLD Pulmonary Function Reading Centre reviewed each spirogram and assigned them a quality score
based on acceptability and reproducibility criteria from the American Thoracic Society (ATS) and European
Respiratory Society (ERS) [20]. Spirometry technicians at BOLD sites were certified before data collection,
received regular feedback on quality and were required to maintain a pre-specified quality standard.
Outcome measures were: 1) airflow obstruction, defined as a post-bronchodilator FEV1/FVC ratio below
the lower limit of normal (LLN) for age and sex [21], based on reference equations for Caucasians derived
from the third US National Health and Nutrition Examination Survey (NHANES) [22]; and 2) spirometric
restriction, defined as a post-bronchodilator FVC below the LLN for height, age and sex, based on the
same reference population.
Statistical analysis
To assess the association of airflow obstruction and spirometric restriction with history of tuberculosis,
multivariable logistic regression models were fitted and adjusted for age (years), sex, body mass index
(underweight: <18.5 kg·m−2; normal: 18.5 to <24 kg·m−2; overweight: 24 to <30 kg·m−2; obese: ⩾30 kg·m−2)
and pack-years of smoking. Additional variables were considered as potential confounders: education (years
of schooling completed), passive smoking (yes or no) and cumulative exposure to dust in the workplace
(years). The association with a history of tuberculosis was estimated for each site using probability weights
to allow for the sampling design at each site and then combined in a random-effects meta-analysis. The
meta-analyses were stratified by gross national income, i.e. high- versus low/middle-income countries. The
level of heterogeneity was summarised using the I2 statistic. We also regressed FEV1/FVC and FVC (litres)
as continuous variables against the same independent variables as above. Sensitivity analyses were
conducted excluding participants presenting with both airflow obstruction and spirometric restriction. In
another set of sensitivity analyses, the association of a history of tuberculosis with airflow obstruction,
spirometric restriction, FEV1/FVC and FVC was assessed omitting all sites with a cooperation rate below
60%. All analyses were conducted using Stata/IC V.12.1 (StataCorp LP, College Station, TX, USA).
Results
The characteristics of the 14050 participants with acceptable post-bronchodilator spirometry who
responded to the core questionnaire and answered the question on history of tuberculosis are presented, by
site, in table 1. There were slightly more females than males and the overall age ranged from 52.3 to
59.6 years across sites. Cumulative smoking exposure, i.e. pack-years, and passive smoking varied widely
across sites. The prevalence of a history of tuberculosis (0.7% in Tirana to 15.4% in Cape Town), airflow
obstruction (6.1% in Tartu and Pune to 19.5% in Cape Town) and spirometric restriction (8.5% in
Vancouver and Tartu to 66.1% in Pune) also varied across sites (tables 1 and 2).
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The unadjusted odds ratio (95% CI) for the association between airflow obstruction and history of
tuberculosis was 3.33 (2.54–4.37). Figure 1 shows adjusted odds ratios (aORs) and 95% confidence
intervals for this association, by gross national income group and site. Overall, the risk of airflow
obstruction in people with a history of tuberculosis was more than twice as much as that of people without
such a history (aOR 2.51, 95% CI 1.83–3.42). This association was stronger in low/middle-income sites
(aOR 3.11, 95% CI 2.30–4.21) and showed no evidence of heterogeneity (I2=0%, p=0.55).
The unadjusted odds ratio (95% CI) for the association between spirometric restriction and history of
tuberculosis was 2.02 (1.42–2.86). Figure 2 shows adjusted odds ratios and 95% confidence intervals by gross
national income group and site for this association. The overall pooled aOR was 2.13 (95% CI 1.42–3.19)
and significant heterogeneity across sites was recorded (I2=62.4%, p<0.001). In high-income sites, there was
no evidence of heterogeneity (I2=0%, p=0.72) but the risk was low and not significant (aOR 1.43, 95%
CI 0.93–2.18). In low-income countries, although the risk was higher and significant (aOR 3.19, 95% CI
1.70–5.99) there was a marked and unexplained heterogeneity in the risk estimates (I2=79.1%, p<0.001).
In both figures 1 and 2, odds ratios are adjusted for age, sex, body mass index and pack-years. Adjustment
for education, passive smoking and cumulative exposure to dust in the workplace did not materially
change the estimates for the effect of tuberculosis. Krakow was excluded from the analyses due to an
insufficient number of participants with both a history of tuberculosis and either airflow obstruction (n=0)
or spirometric restriction (n=2).
A history of tuberculosis was also associated with both decreased FEV1/FVC (β=−3.43, 95% CI −5.05–−1.80;
I2=65.3%, p<0.001) and decreased FVC (β=−0.15, 95% CI −0.23–−0.06; I2=48.6%, p=0.01) (supplementary
figures 1 and 2).
Sensitivity analyses, excluding 482 participants who had both FEV1/FVC<LLN and FVC<LLN, showed
that the magnitude of the effects of tuberculosis reduced slightly but remained statistically significant (aOR
for airflow obstruction 2.13, 95% CI 1.40–3.23; aOR for spirometric restriction 2.11, 95% CI 1.31–3.38),
suggesting that these effects are largely independent of each other.
The omission of sites with a cooperation rate below 60% did not materially change the results
(supplementary figures 3–6).
Discussion
In this population-based study of adults aged 40 years and over, a history of tuberculosis was associated
with increased risk of airflow obstruction. A history of tuberculosis was also associated with spirometric
restriction but mainly in sites in low/middle-income countries.
The strengths of the present study are: 1) its large population-based sample and the inclusion of a great
number of sites; 2) the use of a standardised questionnaire for collection of data on risk factors and
protocol for spirometry across sites; and 3) the use of post- instead of pre-bronchodilator spirometric
measurements. The most convincing effect relates to obstruction in low/middle income countries where
the odds ratio was high (OR 3.11) and the results were consistent between sites (I2=0%).
Our study also has some limitations. One is its cross-sectional nature, which impedes us from drawing
conclusions in terms of temporality and makes us consider the possibility of reverse causation.
Tuberculosis is more common in people with some restrictive diseases such as silicosis, but these are
relatively very rare. Tuberculosis may also be reactivated in those who take corticosteroids, particularly
inhaled corticosteroid treatment recommended in chronic airway disease. However, their use is rare in this
population and even rarer in the low/middle-income countries, where the association between tuberculosis
and airflow obstruction is most pronounced. At some sites, response rates were lower than desirable but
when we omitted all sites with a cooperation rate below 60%, the results did not materially change.
Another limitation is the use of data on a self-reported history of tuberculosis, which may suffer from
under-reporting due to stigmatisation of the diagnosis. However, differential under-reporting due to
stigmatisation between people with and without airflow obstruction or spirometric restriction seems
unlikely. It is also possible that several participants have suffered from tuberculosis and healed without any
treatment, and thus, tuberculosis infection may be underestimated. However, in a study in China, the
magnitude of the association of airflow obstruction with tuberculosis was similar between self-reports and
radiological confirmation [23]. According to ATS/ERS [24], pulmonary restriction is defined by a total
lung capacity (TLC) less than the fifth percentile of the predicted value. This implies measuring TLC by
plethysmography or helium dilution, which is unrealistic in large-scale epidemiological studies such as
this, especially at centres in low/middle-income countries. We are mindful that our choice of FVC as a
surrogate of TLC may lead to false-positive findings in those with increased residual volumes but outside
the clinical environment, the prevalence of this is very low. We are also aware that the use of the
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TABLE 1 Characteristics of participants from 19 sites of the BOLD study with good quality spirometry and data on history of tuberculosis (at least five cases)
Tirana,
Albania
Annaba,
Algeria
Salzburg,
Austria
Vancouver,
BC, Canada
Guangzhou,
China
London,
UK
Tartu,
Estonia
Hannover,
Germany
Reykjavik,
Iceland
Pune, India Fes,
Morocco
Maastricht, the
Netherlands
Manila, the
Philippines
Nampicuan
and Talugtug,
the Philippines
Krakow,
Poland
Lisbon,
Portugal
Cape Town,
South
Africa
Uppsala,
Sweden
Lexington,
KY, USA
Subjects n 939 890 1253 827 461 675 613 680 757 845 768 590 892 722 526 711 846 547 508
Age years 55.4±11.7 53.5±10.9 59.2±12.2 56.8±12.7 54.0±10.6 58.0±12.4 59.6±12.2 57.7±11.1 57.0±12.0 52.3±10.0 54.2±11.9 58.5±12.0 52.7±11.1 54.2±10.6 56.2±11.8 58.5±12.0 53.5±10.5 58.9±11.4 57.0±11.6
Males % 48.9 49.9 46.1 47.3 52.0 46.2 39.1 45.4 51.3 59.8 52.2 46.8 47.5 49.4 49.6 45.3 43.8 47.1 46.4
BMI# kg·m−2 28.0±4.6 28.2±5.6 26.4±4.3 26.7±5.1 23.3±3.2 27.3±5.2 28.4±5.4 27.1±4.6 27.9±5.0 22.1±3.9 27.5±5.2 27.5±4.6 24.4±4.7 21.6±4.1 27.8±4.7 27.9±4.7 27.5±7.3 26.9±4.4 30.6±6.5
Smoking history¶
pack-years
11.5±19.3 10.4±18.3 12.7±20.7 12.1±21.4 11.8±17.7 17.5±27.4 7.4±13.0 14.6±20.4 12.9±24.9 0.7±3.6 6.6±14.9 14.5±19.0 10.6±18.6 12.9±18.4 15.8±25.5 13.1±25.0 11.9±16.1 10.4±16.2 24.4±34.7
Passive smoking % 37.4 10.9 21.8 5.7 23.6 16.6 15.6 18.6 16.8 11.1 11.4 17.7 48.8 47.3 39.3 18.7 50.6 5.8 29.6
Education+ years 10.0±4.6 7.7±5.4 9.8±2.2 15.4±3.4 8.4±3.9 13.6±3.6 13.5±3.8 10.3±2.2 13.2±4.4 4.3±4.3 4.2±5.3 14.9±5.1 9.4±3.6 7.8±3.6 10.4±3.4 8.5±4.9 7.8±3.3 12.8±4.0 12.8±3.3
Cumulative exposure
to dust in
workplace§ years
15.0±14.1 5.6±10.3 5.2±11.7 3.1±7.5 6.9±11.6 4.0±9.7 5.0±10.1 3.3±8.7 4.2±9.6 1.8±5.5 8.5±12.8 3.3±8.8 7.1±10.8 6.1±11.8 10.5±13.4 10.6±14.3 6.8±10.3 5.5±11.3 8.3±12.1
PB-FEV1 L·s−1 2.8±0.8 2.7±0.8 2.9±0.9 3.0±0.9 2.4±0.7 2.7±0.9 2.9±0.9 3.0±0.8 3.0±0.9 2.2±0.6 2.7±0.7 2.9±0.9 2.1±0.6 2.1±0.7 2.9±0.9 2.7±0.9 2.3±0.7 3.0±0.9 2.7±0.9
PB-FVC L 3.5±0.9 3.4±0.9 3.9±1.0 4.0±1.1 3.1±0.8 3.6±1.1 3.8±1.1 3.9±1.0 4.0±1.0 2.7±0.7 3.4±0.9 3.8±1.1 2.6±0.7 2.7±0.8 3.8±1.0 3.4±1.1 3.0±0.9 3.9±1.1 3.5±1.1
History of
tuberculosis %
0.7 2.2 2.9 3.2 3.5 2.1 7.0 3.6 4.0 0.9 1.4 1.4 10.8 3.6 2.8 4.5 15.4 1.1 1.9
Data are presented as mean±SD unless otherwise stated. BOLD: Burden of Obstructive Lung Disease; BMI: body mass index; education: years of schooling complete; PB: post-bronchodilator;
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity. #: missing data for three subjects in Krakow, two in Cape Town and one in Lexington; ¶: missing data for seven subjects in
Manila, three in Nampicuan and Talugtug, three in Krakow, two in Vancouver, two in Cape Town, two in Maasstricht, one in Reykjavik, one in Fes and one in Uppsala; +: missing data for seven
subjects in Nampicuan and Talugtug, five in London, one in Tartu, one in Fes, one in Lisbon and one in Cape Town; §: missing data for four subjects in Maasstricht.
TABLE 2 Estimated population prevalence of airflow obstruction and spirometric restriction in 19 sites of the BOLD study with good quality spirometry and data on
history of tuberculosis (at least five cases)
Tirana,
Albania
Annaba,
Algeria
Salzburg,
Austria
Vancouver,
BC, Canada
Guangzhou,
China
London,
UK
Tartu,
Estonia
Hannover,
Germany
Reykjavik,
Iceland
Pune,
India
Fes,
Morocco
Maastricht,
the
Netherlands
Manila,
the
Philippines
Nampicuan
and Talugtug,
the
Philippines
Krakow,
Poland
Lisbon,
Portugal
Cape
Town,
South
Africa
Uppsala,
Sweden
Lexington,
KY, USA
Subjects n 939 890 1253 827 461 675 613 680 757 845 768 590 892 722 526 711 846 547 508
Airflow obstruction % 8.9 6.4 17.4 13.5 7.6 17.6 6.1 8.2 11.3 6.1 8.9 18.8 9.4 15.2 13.5 8.3 19.5 9.6 14.4
Spirometric restriction % 16.1 26.5 9.3 8.5 29.9 17.8 8.5 9.0 12.5 66.1 19.3 10.1 62.7 56.7 10.1 10.7 46.7 10.2 26.2
Response rate# % 82.3 94.6 65.0 26.0 87.0 17.0 49.0 59.0 81.0 97.0 98.0 48.0 58.0 85.5 78.0 10.0 63.0 61.0 14.0
Cooperation rate¶ % 84.0 94.6 67.0 51.0 87.0 37.0 70.0 61.0 84.0 97.0 98.0 55.0 58.0 86.2 79.0 27.0 68.0 63.0 27.0
Airflow obstruction was defined as a forced expiratory volume in 1 s/forced vital capacity (FVC) ratio below the lower limit of normal (LLN). Spirometric restriction was defined as an FVC
below the LLN. BOLD: Burden of Obstructive Lung Disease. #: denominator comprises people of unknown eligibility status who could not be contacted; only known participants
considered ineligible were excluded. ¶: denominator comprises only participants who were contacted and eligible.
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NHANES reference equations in our spirometry measurements may overemphasise lung function
abnormality at some study sites but the effect of this is unlikely to be differential as the analyses were done
within each site (the sites are fairly ethnically homogeneous) and only then were meta-analysed. In
addition, the results from the binary outcomes (FEV1/FVC<LLN and FVC<LLN) are supported by those
of the continuous outcomes (FEV1/FVC and FVC), which are independent of reference equations.
Low/middle-income sites
Tirana, Albania
Site
Annaba, Algeria
Guangzhou, China
Pune, India
Fes, Morocco
Manila, the Philippines
Cape Town, South Africa
Subtotal (I2=0.0%, p=0.550)
High-income sites
Salzburg, Austria
Vancouver, BC, Canada
London, UK
Tartu, Estonia
Hannover, Germany
Reykjavik, Iceland
Maastricht, the Netherlands
Lisbon, Portugal
Uppsala, Sweden
Lexington, KY, USA
Subtotal (I2=48.4%, p=0.042)
Overall (I2=31.7%, p=0.097)
0.2 1.0
OR
5.0
2.79 (0.63–12.35)
2.96 (0.91–9.61)
OR (95% CI)
0.62 (0.09–4.22)
11.73 (1.72–79.97)
1.15 (0.13–10.38)
2.64 (1.37–5.11)
3.49 (2.19–5.57)
Nampicuan and Talugtug, the Philippines 3.42 (1.72–6.80)
3.11 (2.30–4.21)
2.50 (1.17–5.33)
1.55 (0.40–5.98)
4.71 (1.26–17.56)
1.13 (0.33–3.85)
1.17 (0.33–4.16)
0.87 (0.31–2.49)
3.14 (0.50–19.66)
5.71 (2.81–11.61)
2.45 (0.29–20.52)
0.23 (0.02–2.27)
1.98 (1.15–3.41)
2.51 (1.83–3.42)
3.63
5.22
Weight %
2.34
2.34
1.83
10.68
13.98
10.25
50.27
9.24
4.24
4.41
4.93
4.65
6.17
2.54
9.91
1.95
1.69
49.73
100.00
FIGURE 1 Odds ratios of airflow obstruction for a history of tuberculosis, by gross national income group (low/middle versus high) and site. All
models were adjusted for age, sex, body mass index and pack-years of smoking.
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OR
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3.19 (1.70–5.99)
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Weight %
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3.39
8.75
9.62
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53.67
6.35
4.67
3.70
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4.23
6.57
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4.64
2.77
4.26
46.33
100.00
FIGURE 2 Odds ratios of spirometric restriction for a history of tuberculosis, by gross national income group (low/middle versus high) and site. All
models were adjusted for age, sex, body mass index, and pack-years of smoking.
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Our findings add to existing knowledge and support the majority of previous smaller studies that have
reported an association between airflow obstruction and a history of tuberculosis [10, 11, 25]. We also
confirm findings from the few occupational and small hospital-based studies that have observed a decline
in lung function associated with both history of and radiographically confirmed tuberculosis [14–18].
Although it is widely accepted that tuberculosis, and the healing process the lung undergoes during and
after treatment, can cause scarring that leads to loss of parenchymal tissue and restrictive spirometry, it is
not clear what mechanisms explain airflow obstruction associated with tuberculosis. The finding that
tuberculosis is associated with airflow obstruction, and not only with spirometric restriction, suggests that
this is not solely the result of parenchymal scarring. One possibility is that this is caused by bronchiectasis
and bronchial stenosis, which can occur as a result of tuberculosis [26]. Another possibility is that this is
caused by a dysregulation of macrophages arising from latent intracellular infection [27]. Macrophages in
the lung act primarily to kill bacteria or to facilitate wound healing and resolution [28], and it is widely
accepted that they play a central role in the remodelling that causes chronic airflow obstruction. It is
possible that latent mycobacteria in lung macrophages could lead to maintenance of inflammation in the
lung and more aggressive remodelling of the airways [28, 29].
In summary, a history of tuberculosis was associated with both airflow obstruction and spirometric
restriction. Nevertheless, large longitudinal studies with post-bronchodilator spirometry are recommended
to confirm or refute these findings. With the continuing spread of tuberculosis in developing countries, an
increasing incidence of multidrug-resistant disease and an ageing world population, it is important to
improve our understanding of the mechanisms that link tuberculosis to airflow obstruction and COPD,
and to devise effective strategies to limit this problem.
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